Zevin Asset Management LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,174 shares of the company’s stock, valued at approximately $207,000.
A number of other hedge funds also recently bought and sold shares of JNJ. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the last quarter. State Street Corp lifted its stake in Johnson & Johnson by 0.6% in the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after acquiring an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 3.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the period. Finally, California Public Employees Retirement System lifted its stake in Johnson & Johnson by 2.7% in the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock worth $1,919,726,000 after acquiring an additional 310,473 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
Johnson & Johnson Trading Down 0.8 %
NYSE JNJ opened at $161.05 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The firm’s fifty day moving average price is $158.62 and its 200 day moving average price is $166.91. The company has a market capitalization of $418.53 billion, a price-to-earnings ratio of 33.69, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.96%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 94.56%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
